/ABCZF

ABCZF Stock - Abcam plc

Q: What is the analyst price target for ABCZF?

Analyst price target information is not currently available for ABCZF.

Q: What is ABCZF's market cap?

Market capitalization information is not currently available for ABCZF.

Healthcare|Biotechnology|OTC

$22.25+0.68%

+$0.15 (+0.68%) • Nov 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $24.48

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ABCZF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.86

52W High$22.25

52W Low$22.25

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2022	FY2021	FY2020	FY2019
Revenue	$301.56M	$361.70M	$315.40M	$297.70M	$260.00M
Gross Profit	$124.71M	$270.50M	$224.60M	$211.80M	$180.20M
Gross Margin	41.4%	74.8%	71.2%	71.1%	69.3%
Operating Income	$-55,712,616	$-10,100,000	$7.10M	$25.80M	$9.90M
Net Income	$169.82M	$-8,500,000	$4.40M	$14.60M	$12.50M
Net Margin	56.3%	-2.4%	1.4%	4.9%	4.8%
EPS	$0.00	$-0.04	$0.02	$0.07	$0.06

Company Overview

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

Visit Website